 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Isis Team Reports on Identification of Argonaute-, RISC-Independent siRNAs
July 26, 2012
Isis Team Reports on Identification of Argonaute-, RISC-Independent siRNAs
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Isis Studies Suggest Therapeutic Potential of Single-Stranded RNAi Molecules
September 6, 2012 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - Alnylam Provides Timelines for Drug Programs, Offers No Formal Guidance on Partnerships
February 16, 2012 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Isis; Allergan; Stanford; and More
January 12, 2012 / Gene Silencing News - Alnylam, Isis Announce Notice of Allowance for RNAi-Related Patent Application
December 17, 2009 / Gene Silencing News